PI3 Kinase Isoforms in Purinergic Mesenchymal Stromal Cells

被引:1
|
作者
Kotova, P. D. [1 ]
Bystrova, M. F. [1 ]
机构
[1] Russian Acad Sci, Inst Cell Biophys, FRC PSCBR RAS, Pushchino 142290, Moscow Oblast, Russia
来源
BIOLOGICHESKIE MEMBRANY | 2020年 / 37卷 / 02期
关键词
mesemchymal stromal cells; Ca2+ signaling; purinergic transduction; PI3; kinase;
D O I
10.31857/S0233475520020073
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
By using the transcriptom analysis it was demonstrated that mesemchymal stromal cells (MSCs) from the human adipose tissue express alpha-, beta-, and delta-isoforms of PI3 kinase (PI3K) from class I, while the PI3K gamma isoform is not expressed. The contribution of PI3K isoforms to purinergic transduction in MSCs was evaluated with the Ca2+-imaging approach and Ca2+ dye Fluo-4. As was shown, Ca2+ transients elicited by ATP in MSCs could be canceled by the PI3K alpha and PI3K beta inhibitors, GSK 1059615 and AZD 6482, respectively. The overall data indicated that most (69%) of MSCs were capable of generating robust ATP responses provided that PI3K alpha was sufficiently active. Yet, a small (15%) subpopulation of purinergic MSCs additionally employed the PI3K beta isoform to transduce extracellular ATP.
引用
收藏
页码:156 / 160
页数:5
相关论文
共 50 条
  • [21] PI3 Kinase, mTOR, and AKT Pathways
    Ramalingam, Suresh S.
    Khuri, Fadlo R.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : S1059 - S1060
  • [22] PI3 Kinase Inhibitors in the Clinic: An Update
    Kurtz, Jean-Emmanuel
    Ray-Coquard, Isabelle
    ANTICANCER RESEARCH, 2012, 32 (07) : 2463 - 2470
  • [23] PI3 KINASE INHIBITORS: PROGRESS AND CHALLENGES
    Workman, P.
    ANNALS OF ONCOLOGY, 2009, 20 : 25 - 25
  • [24] Brain penetrant PI3 kinase inhibitors
    Heffron, Timothy P.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [25] Importance of PI3 kinase family for crosstalk between chronic lymphocytic leukemia B cells and the stromal microenvironment: Therapeutic implications
    Niedermeier, Matthias T. W.
    Rawluk, Justyna
    Knight, Zachary
    Shokat, Kevan
    Wierda, William G.
    Keating, Michael J.
    Burger, Jan A.
    BLOOD, 2007, 110 (11) : 341A - 341A
  • [26] Epithelial-mesenchymal transformation during palate fusion requires PI3 kinase activity
    Kang, P
    Svoboda, KKH
    MOLECULAR BIOLOGY OF THE CELL, 2000, 11 : 60A - 60A
  • [27] Survival of acute myeloid leukemia cells requires PI3 kinase activation
    Xu, Q
    Simpson, SE
    Scialla, TJ
    Bagg, A
    Carroll, M
    BLOOD, 2003, 102 (03) : 972 - 980
  • [28] TEGDMA induced apoptosis in human pulp cells is PI3 kinase dependent
    Spagnuolo, G
    Galler, K
    Schmalz, G
    Rengo, S
    Schweikl, H
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 : R122 - R122
  • [29] An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome
    Begg, Malcolm
    Amour, Augustin
    Jarvis, Emily
    Tang, Teresa
    Franco, Sara Santos
    Want, Andrew
    Beerahee, Misba
    Fernando, Disala
    Karkera, Yakshitha
    Sander, Clare
    Southworth, Thomas
    Singh, Dave
    Clark, Jonathan
    Nejentsev, Sergey
    Okkenhaug, Klaus
    Condliffe, Alison
    Chandra, Anita
    Cahn, Anthony
    Hall, Edward Banham
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 79
  • [30] Assessment of PI3 kinase as a druggable target in melanoma
    Aziz, S. A.
    Pick-Golan, E.
    McCarthy, M. M.
    Flaherty, K. T.
    Camp, R. L.
    Rimm, D. L.
    Kluger, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)